Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCAR1 Retreatment in Alveolar Soft Part Sarcoma
NCT06813417Phase 1Active, not recruiting
- Sponsor
- University of Calgary
- Start
- Jan 2025
- Primary completion
- Jan 2030
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GCAR1 in alveolar soft part sarcoma (ASPS), sponsored by University of Calgary. Primary endpoint: Treatment Response at 1 year. Started Jan 2025; status: active, not recruiting.
02
Drugs
GCAR1
03
Conditions
alveolar soft part sarcoma (ASPS)
Beyond the preview
Go deeper on NCT06813417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06813417.